Vis enkel innførsel

dc.contributor.authorEconomou, Mario A
dc.contributor.authorLaukeland, Helene Kolstad
dc.contributor.authorGrabska-Liberek, Iwona
dc.contributor.authorRouland, Jean-Francois
dc.date.accessioned2019-09-18T06:28:48Z
dc.date.available2019-09-18T06:28:48Z
dc.date.created2019-02-26T15:24:10Z
dc.date.issued2018
dc.identifier.citationClinical Ophthalmology. 2018, 12 2399-2407.nb_NO
dc.identifier.issn1177-5467
dc.identifier.urihttp://hdl.handle.net/11250/2617319
dc.description.abstractBackground: Lack of efficacy due to bad compliance caused by intolerance issues is the main reason for a change to a better tolerated ocular treatment, such as using preservative-free (PF) eye drops. Aim: To assess the efficacy and local tolerance after 12 months and patient satisfaction regarding local treatment tolerance and handling at inclusion and after 6 months of PF latanoprost compared to preserved glaucoma eye drops. Methods: This was an international, prospective, and observational real-life study. Up to three visits, one at inclusion and two follow-up visits (one after 6 and one after 12 months) were planned. Efficacy, local tolerance, and patient satisfaction were the main evaluation criteria. Results: Data from 721 patients were available for the statistical analysis. Overall, 64.8% (467/721) of patients switched treatment before inclusion: 62.2% in the preserved and 68.9% in the PF latanoprost group. IOP values were similar between PF latanoprost and preserved eye drops and remained stable at all visits. Ocular signs and symptoms improved after switching to PF latanoprost; the prevalence of conjunctival hyperemia was significantly lower (P=0.0015) at both follow-up visits. At follow-up visit 1, 49.5% of the patients who switched to PF latanoprost decreased or stopped the use of artificial tears. Satisfaction regarding tolerance in patients using PF latanoprost improved significantly after the switch from preserved eye drops to PF latanoprost (88.9% and 42.5%, respectively, P<0.0001). Conclusion: This first real-life study showed that PF latanoprost was as efficacious but better tolerated than preserved eye drops over a sustained period of 12 months, while providing a significantly higher patient satisfaction and potentially allowing improvement in the patient’s daily life.nb_NO
dc.language.isoengnb_NO
dc.publisherDovepressnb_NO
dc.rightsNavngivelse-Ikkekommersiell 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/deed.no*
dc.titleBetter tolerance of preservative-free latanoprost compared to preserved glaucoma eye drops: The 12-month real-life FREE studynb_NO
dc.typeJournal articlenb_NO
dc.typePeer reviewednb_NO
dc.description.versionpublishedVersionnb_NO
dc.source.pagenumber2399-2407nb_NO
dc.source.volume12nb_NO
dc.source.journalClinical Ophthalmologynb_NO
dc.identifier.doi10.2147/OPTH.S176605
dc.identifier.cristin1680861
dc.description.localcodeOpen Access. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.nb_NO
cristin.unitcode1920,11,0,0
cristin.unitcode194,65,15,0
cristin.unitnameKlinikk for ØNH, kjeve- og øyesykdommer
cristin.unitnameInstitutt for klinisk og molekylær medisin
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse-Ikkekommersiell 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse-Ikkekommersiell 4.0 Internasjonal